Every Monday we share a quick “best of” from the week that was with our Inner Circle members. What’s trending in the Femtech Insider community and beyond? We’ve got you covered! In this week’s brief we talk about Organon’s Forendo Pharma Acquisition and New Endometriosis Treatments, plus…

  • New Femtech Industry Events 2022
  • The Rise of Women’s Health Platform Companies
  • Inner Circle Fireside Chats 2022

Spotlight: Endometriosis

Last week women’s health pharma company and Merck spin-off Organon, completed its recently announced acquisition of Forendo Pharma, a clinical-stage drug development company focused on novel treatments in women’s health. Forendo’s lead candidate, FOR-6219, is an investigational, potentially first-in-class oral 17β-hydroxysteroid dehydrogenase type 1 (HSD17B1) inhibitor entering Phase 2 clinical development for endometriosis.

You’ve found some of our exclusive Inner Circle Content.

This article is only available for our Inner Circle Members. To read on: